Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

UPDATED: Biogen R&D chief Doug Williams joins exodus to run a biotech upstart

Biogen's high-profile R&D chief, Doug Williams, has heard the siren song of a biotech startup. Near midday on Friday, the Big Biotech put out word that Williams will be leaving Biogen to helm a fledgling, and unnamed, company. All that is known now is that Williams is the first member of a new company that will focus on cancer diagnostics and therapies.

Takeda chairman Hasegawa out as JPMA vice president

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

OxyContin sales put Purdue's Sackler family on Forbes rich list

The Busches, the Mellons, the Rockefellers--they're some of America's richest families. But one blockbuster pain drug has put a family of pharma-founders ahead of them all in the wealth department.

Takeda's Hasegawa out as JPMA VP after firm called to task on Blopress

Takeda Pharmaceutical Chairman Yasuchika Hasegawa was removed as vice president by the Japan Pharmaceutical Manufacturers Association, according to an updated leadership list that was confirmed by a company spokesman.

Nathalie Adda named Enanta CMO

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Viehbacher returns to lead Swiss billionaire's $2B biotech fund

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Allergan CEO: 'The cuts are done' at layoffs-plagued Irvine campus

The good news for Allergan's ex-headquarters in Irvine, CA: CEO Brent Saunders says the operations there are still key to the company. More good news: The layoffs that hit that site are now over and done, he says.

UPDATED: Bristol-Myers rips up its R&D group, adding, eliminating and moving 800-plus

Bristol-Myers Squibb's R&D organization is being revamped in a major shakeup that will see a new research center open in Cambridge, MA, two other research centers close, with hundreds of jobs being relocated in Massachusetts and Connecticut while about 100 researchers are axed as the Big Biotech shutters its discovery work in virology.

Vectura poaches key AZ respiratory exec to replace departing CEO

What's in the water at AstraZeneca? Maybe it's an elixir for top managers who want to run a smaller drugmaker. Maybe it's an anti-Big Pharma potion. Either way, it means a second high-level exec has left the U.K.-based drugmaker for a CEO post elsewhere.

Pharma in India shakes up executive ranks at Ranbaxy, Cipla, others

A slew of senior executives at the Ranbaxy unit of India's Sun Pharmaceutical and Cipla are likely polishing up their Linkedin profiles and calling head hunters as something of a cull sweeps through management ranks at those companies and wider, highlighting deep changes in the industry.